Lenvatinib相关论文
目的 全面客观评价Lenvatinib联合程序性死亡受体-1(PD-1)抑制剂对晚期肝癌治疗的安全性和有效性,为临床指导实践提供可靠证据.方......
目的 Our previous study showed that lenvatinib upregulated programmed cell death 1ligand 1(PD-L1)in hepatoma cells,where......
Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory diff
...
Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung canc
...
Objective An open-label,randomized,multicentre phase 3 trial(REFLECT)compared the efficacy and safety of lenvatinib vers......
The usefulness of thyroglobulin doubling time to determine optimal timing to initiate Lenvatinib the
Background: Early initiation of Lenvatinib in radioactive-iodine-refractory differentiated thyroid cancer (RR-DTC) patie......
The proportion of liver transplantation(LT)for hepatocellular carcinoma(HCC)has kept on increasing over the past years a......
以3-甲氧基苯胺和3,3-二乙氧基丙酸乙酯为原料,通过串联的甲酰化-加成环化-氯化反应和氧化酰胺化反应,制备得到了抗癌药Lenvatinib......
,Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliar
Background: A therapeutic strategy involving combined treatment with lenvatinib plus pembrolizumab (LEP) has demonstrate......
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
BACKGROUND The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer remains challeng......
Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment:A cas
BACKGROUND Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients ......
目的探讨乐伐替尼靶向调节VEGFR/PI3K/AKT治疗晚期甲状腺癌的作用机制。方法选取100例晚期分化型甲状腺癌患者,采用口服乐伐替尼,......
1例55岁男性患者,因肝癌晚期伴腹腔转移,术后口服仑伐替尼(12mg,qd),1个月后抗癌方案调整为仑伐替尼联合卡瑞利珠(200mg,q2w,ivgtt......
Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenv
BACKGROUND Hepatocellular carcinoma(HCC)accompanied by portal vein tumour thrombus(PVTT)presents an aggressive disease c......
肝细胞癌(HCC)是常见的恶性肿瘤,在我国其发病率和死亡率分别位列各类恶性肿瘤的第四位和第二位,由于HCC起病隐匿,大多数患者发现......
目的:研究乐伐替尼联合PD-1抗体对NSCLC大鼠血清VEGF、免疫功能及生存时间的影响。方法:将50只雄性健康wistar大鼠随机分为5组,每......
Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unr
BACKGROUND Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma......
目的:检测奥美拉唑对新型分子靶向药物仑伐替尼杀伤非小细胞肺癌(NSCLC)的影响并阐明其分子机制。方法:体外培养人NSCLC细胞系A549......
仑伐替尼是一种多靶点酪氨酸激酶抑制剂,可作用于血管内皮生长因子受体(VEGFR)及成纤维细胞生长因子受体(FGFR)等多个靶点抑制血管......
乐伐替尼是一种口服的多受体酪氨酸激酶(RTK)抑制剂。以对硝基苯基氯甲酸酯为原料,经两次酰化反应得到关键中间体1-(2-氯-4-羟基苯......
Background:Current chemotherapy for acute myeloid leukemia(AML)mainly involves cytotoxic agents such as doxorubicin(DNR)......
为了控制乐伐替尼的质量,本文以4-氨基-3-氯苯酚为起始原料,经酰化、成脲得到中间体1-(2-氯-4羟基苯基)-3-环丙基脲(4),然后该中间......
BACKGROUND In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma......
Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospecti
BACKGROUND Lenvatinib has become an indispensable part of treatment regimens for patients with advanced hepatocellular c......
为了控制原料药乐伐替尼质量,分别以化合物1和3为原料,经酰化、胺化,成脲得到2和5,然后这两个中间体发生亲核取代反应得到乐伐替尼......
期刊
Clear-cell variants of follicular carcinoma are rare subtypes of thyroid cancer. There is no unified view of the histopa......
<正>日本药企卫材(Eisai)近日宣布,已向欧洲药品管理局(EMA)提交其内部开发的新型抗癌药lenvatinib(乐伐替尼)的扩大适应症申请,寻......
期刊
2-甲氧基-4-氨基苯甲酸甲酯(4)与米氏酸缩合后,经环合、氯代及氨解制得4-氯-7-甲氧基喹啉-6-甲酰胺(8)。另以邻氯硝基苯(9)经还原......
期刊
<正>卫材(Eisai)近日公布了实验性抗癌药物lenvatinib(E7080)Ⅲ期SELECT研究的数据。该研究是一项多中心、随机、双盲、安慰剂对照......
目的制备lenvatinib,并对其工艺进行改进,以简化操作,提高收率。方法以4-氨基水杨酸(2)为原料,经甲基化,与麦氏酸缩合、高温环合、......
期刊
甲状腺癌是一种常见的内分泌腺恶性肿瘤。2013年，在美国约有60220甲状腺癌患者，其中1850例患者发生死亡。绝大多数(93%)甲状腺癌为分......
学位
